Abbott Labs ABT-874 for Treatment of Crohn’s Disease
November 11, 2004 by admin · Leave a Comment
On November 11, 2004 the results of an Abbott Labs Phase 2 Crohn’s disease clinical trial examining the safety and efficacy of ABT-874 were published in the New England Journal of Medicine. , ABT-874 is a monoclonal antibody designed to target interleukin-12 (IL-12). The authors concluded that treatment with ABT-874 may have caused clinical responses [...]
Elan/Biogen Idec’s Antegren (Natalizumab) for Treatment of Multiple Sclerosis
July 26, 2004 by admin · Leave a Comment
On July 26, 2004 Elan Corp.’s application for approval of its multiple sclerosis (MS) drug Antegren was accepted for review by the FDA. Elan has developed Antegren with U.S. partner Biogen Idec. The company has stated that this therapy represents a new approach in the treatment of MS and is expected to eventually generate annual [...]